ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs MXN
16.5541
-0.01%
Brent Oil
83.455
-0.09%
Bitcoin
71,121.39
-0.46%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Atea Pharmaceuticals Inc (AVIR)

  7. Atea Pharmaceuticals Inc (AVIR) Noticias

AVIR

Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AVIR
FechaHoraFuenteTítuloSímboloCompañía
14/05/202415:43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202415:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
07/05/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
29/04/202406:00GlobeNewswire Inc.Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
27/03/202406:00GlobeNewswire Inc.Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsNASDAQ:AVIRAtea Pharmaceuticals Inc
28/02/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
21/02/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
02/02/202420:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
01/02/202415:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/01/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
03/01/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
13/11/202306:00GlobeNewswire Inc.Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202315:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202306:00GlobeNewswire Inc.Atea Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:AVIRAtea Pharmaceuticals Inc
02/11/202306:00GlobeNewswire Inc.Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
01/11/202306:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
06/09/202306:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
08/08/202315:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/08/202306:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
21/06/202315:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVIRAtea Pharmaceuticals Inc
15/06/202306:00GlobeNewswire Inc.Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir CombinationNASDAQ:AVIRAtea Pharmaceuticals Inc
12/06/202307:20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
05/06/202315:20GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
30/05/202306:00GlobeNewswire Inc.Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
23/05/202315:05GlobeNewswire Inc.Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202315:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202315:05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/05/202315:05GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
28/04/202315:10Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVIR

Su Consulta Reciente

NASDAQ
MSFT
Microsoft
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AMZN
Amazon.com
AMEX
XLV
Health Care Select Sector
NYSE
CVX
Chevron
AMEX
XLE
Energy Select Sector SPDR
NYSE
NKE
Nike
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
CCOM
US30
US 30
FX
EURUSD
Euro vs US Dollar
NYSE
AXP
American Express
USI
USTECH100
US Tech 100
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados